anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Biallelic variants in thiamine pyrophosphokinase 1 ( TPK1 ) are known to cause thiamine metabolism dysfunction syndrome 5 (THMD5). This disorder is characterized by neuroregression, ataxia and dystonia with basal ganglia abnormalities on neuroimaging. To date, 27 families have been reported with THMD5 due to variants in TPK1 .
METHODS: We ascertained three individuals from three unrelated families. Singleton exome sequencing was performed on all three individuals, followed by in silico mutagenesis of the mutant TPK protein. Additionally, we reviewed the genotypic and phenotypic information of 27 previously reported individuals with THMD5.
RESULTS: Singleton exome sequencing revealed a novel homozygous variant c.620A>T p.(Asp207Val) in TPK1 (NM_022445.4) in all three individuals. In silico mutagenesis of the mutant protein revealed a decrease in protein stability and altered interactions with its neighboring residues compared to the wild-type protein. Thus, based on strikingly similar clinical and radiological findings compared to the previously reported individuals and with the support of in silico mutagenesis findings, the above-mentioned variant appears to be the probable cause for the condition observed in the affected individuals in this study.
CONCLUSION: We report a novel homozygous variant in TPK1 , which appears to be recurrent among the Indian population.
A 45-day feeding assay was carried out to evaluate the effects of crescent levels of dephytinized rice bran protein concentrate (DRBPC) on growth performance, nutrient deposition, plasma and liver parameters of jundiá Rhamdia quelen. Five experimental diets were formulated with inclusion of 0 (control), 10, 15, 20, and 30% of DRBPC. In total 500 jundiás (initial body weight 6.28 ± 0.12 g) were allocated in 20 tanks (230 L) to give four groups for each treatment. Fish were fed to apparent satiation for 45 days. Weight gain and specific growth rate were evaluated by cubic regression analysis (P < 0.05) and displayed maximal growth on the inclusion level of 25% of DRBPC. The results indicated that fish fed DRBPC15 and DRBPC30 had lower body protein deposition and hepatosomatic index compared to CONTROL diet, respectively. No significant differences (P > 0.05) were assessed in plasma parameters. The alanine aminotransferase activity was higher in fish fed DRBPC30 compared to CONTROL group. The present study has demonstrated that DRBPC displayed significant nutritional quality for the jundiá. Thus, this new ingredient could be included as a protein source in fish for minimizing the use of fish meal.
OBJECTIVES: I. Determine the anti-tumor activity of docetaxel and carboplatin in women with metastatic adenocarcinoma of the breast. II. Determine the objective response rate, time to progression, and survival in patients treated with this regimen. III. Determine the toxic effects of this regimen in these patients. IV. Assess the common functional polymorphisms in genes involved in chemotherapeutic response to improve prediction of clinical outcomes and provide insight into the potential for genotype-specific drug dosage.

OUTLINE: This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.
Breast cancer patients treated with radiotherapy after surgery are prospectively enrolled. Thyroid function is evaluated mainly by the measurement of thyroid-stimulating hormone (TSH), free triiodo-thyronine (FT3) and free thyroxine (FT4). Thyroid function is regularly assessed before and after radiotherapy. The radiation technique and thyroid dose parameters are assessed. Development of subclinical or biochemical hypothyroidism is noted. The incidence and risk factors of hypothyroidism is analyzed. The dose-volume constraints that correlate with functional impairment of the thyroid in breast cancer patients treated with radiotherapy is discussed.
PURPOSE:A hybridoma, obtained by the plasmogamy of murine lymphocytes prepared by using sperms or seminal plasmas of BRTFM strain mice as an immunological source with myelomatous cells, useful as a diagnostic agent, and capable of producing an antibody for murine sperms and seminal plasma antigen. CONSTITUTION:Sperms or seminal plasmas of BRTFM strain mice are injected into a female mouse to immunize the mouse, and then the pancreas are taken out to isolate lymphocytes. Myelomatous cells of a mouse are cultivated separately and mixed with the isolated lymphocytes in the culture fluid, and a fusing agent, e.g. polyethylene glycol, is added thereto to carry out the plasmogamy. The resultant hybridoma is then cultivated in a culture fluid, e.g. HAT culture fluid, selective for the hybridoma, and the antibody value in the culture fluid is then checked to select and isolate only the hybridoma producing the antibody. The resultant hybridoma is useful as an analyzing means for mechanisms of fertilization, differentiation and cancinogenesis.
Computer-adaptive SAFE will consist of 4 60-minute sessions. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method. Session 4 will focus on effective strategies to communicate with a sexual partner. Computer-adaptive SAFE will use an audio computer-assisted self-interviewing (ACASI) format.
Background: Fiberoptic intubation is the preferred method of intubation in patients with acute symptoms or signs of cervical myelopathy. This approach minimizes cervical spine movements to prevent new neurologic deficits or further neurologic injury, and is the safer method to secure the airways in patients with foreseen difficult intubation. In these patients anaesthesia induction is aimed to prevent cervical spine movements and to maintain hemodynamic stability. The most commonly reported technique for anaesthesia induction in patients with cervical myelopathy is based on local anaesthesia and propofol administration. Aim of this trial is to compare propofol-based anaesthesia vs. sevoflurane-based anaesthesia induction in patients with cervical myelopathy receiving oral or nasal fiberoptic intubation.

Methods: This randomized controlled trial is designed to prove equivalence. A series of 116 patients aged between 18 and 75 years, with cervical myelopathy will be enrolled. In all patients topical anaesthesia will be accomplished before anaesthesia induction. Patients will be randomly assigned to one of two anaesthesia induction strategies (sevoflurane + O2 + air or propofol + O2 + air). When loss of consciousness occurs (indicated by Bispectral index values between 40 and 50), oral or nasal fiberoptic intubation will be performed. The hemodynamic effects of the anaesthesia induction strategies will be assessed measuring mean arterial pressure at 4 time points: before anaesthesia induction (T1: baseline), at the end of anaesthesia induction when an adequate sedation level, with Bispectral index values 40-50, is achieved (T2: sedation steady state); immediately after placement of endotracheal tube (T3: intubation); five minute after tracheal intubation (T4: post-intubation). Secondary end-points of the study include the incidence of apnoea during induction process, diagnosed as absence of carbon dioxide trace for more than 10 seconds, the incidence of induction complications, defined as presence of laryngospasm, coughing and patient movement, and intubation conditions, defined as cord opening.

Discussion: We present the development phase of this anaesthesiological trial. A total of 40 patients have been enrolled from April 2009.
The invention relates to a throat-clearing and sore-throat-relieving tea which is prepared from the following raw material medicines: radix Ophiopogonis, rhizoma Polygonati Odorati, semen Armeniacae amarum, flos Chrysanthemi, semen Scaphii Lychnophori, and herba Menthae. The invention also provides application of the traditional Chinese medicine in preparing a medicament for clearing throat and relieving sore throat. The advantages are that: 1. the invention mainly takes flowers, fruits and seeds as medicines, has dual purposes of medicine and food, is safe without side effect, and is suitable for being decocted to drink instead of tea. 2. The tea prepared by the invention can play an instant effect on swollen and red throat, pain, hoarseness, phlegm asthma and cough. 3. The components of the traditional Chinese medicines and the proportion of the components are screened through experiments, and the tea has the advantage of remarkable effect.
Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material, such as a hydrogel, lipogel, or highly viscous sol. The compositions also include, or are administered in conjunction with, an enhancer in an amount effective to maximize expression of or binding to receptors and enhance RME of the compound into the cells. This leads to high transport rates of compounds to be delivered across cell membranes, facilitating more efficient delivery of drugs and diagnostic agents.  Compositions are applied topically orally, nasally, vaginally, rectally, and ocularly. The enhancer is administered with the composition or separately, either systemically or preferably locally. The compound to be delivered can also be the enhancer.
Junyikang prepn. is made by mixed fermentation or separate fermentation of one or more kinds of bifidobacteria and one or more kinds of intestine beneficial bacterium and combination with one or more kinds of bifido factor. The bifidobacteria used include bifidobacterium infontis, bifidobacterium longum, bifidobacterium breve and bifidobacterium bifidum. The intestine beneficial bacteria used include clostridium butyrium, lactobacillus acidophilus and stretococcus thermophilus. This prepn. possesses the advantages of quick improvement the ecological balance in intestine and obvious curing effect to dysentery and constipation.
BACKGROUND: Imatinib (IM) is the primary treatment for patients with chronic-phase CML (CML-CP). However, an increasing number of CML-CP patients have developed resistance to IM. Our study aims to explore the expression of miR-629-5p in extracellular vesicles (EVs) from both IM-sensitive (K562) and resistant (K562-Re) CML cell lines and to investigate the impact of regulating miR-629-5p expression on the biological characteristics of K562 and K562-Re cells.
METHODS: Assess miR-629-5p expression levels in IM-sensitive and resistant CML cell lines. Separate EVs and verify it. EVs from K562-Re cells were co-cultured with K562 cells to detect the expression level of miR-629-5p. Target genes of miR-629-5p were determined and validated through luciferase experiments. Examined by manipulating miR-629-5p expression in cells using transfection techniques. The expression level of phosphorylated proteins in the PI3K/AKT/mTOR signaling pathway after IM was detected in CML cell lines. In K562-Re cells, the expression level of phosphorylated protein in the PI3K/AKT/mTOR signaling pathway was detected after single transfection of miR-629-5p inhibitor and cotransfection of miR-629-5p inhibitor and siSENP2.
RESULTS: Increasing concentrations of EVs from K562-Re cells elevated miR-629-5p expression levels. The expression levels of miR-629-5p in CML cells varied with IM concentration and influenced the biological characteristics of cells. SENP2 was identified as a target gene of miR-629-5p. Furthermore, miR-629-5p was found to modulate the SENP2/PI3K/AKT/mTOR pathway, impacting IM resistance in CML cells.
CONCLUSION: EVs from IM-resistant CML cells alter the expression of miR-629-5p in sensitive cells, activating the SENP2/PI3K/AKT/mTOR pathway and leading to IM resistance.
Patients in the experimental group were informed that cold spray would be applied to their arm in a supine position to reduce procedure-related pain. For femoral artery angiography, the central part of the inguinal access area was targeted, and for radial angiography, 2 cm above the styloid process of the radial bone was targeted, and cold spray (Chloroethyl spray) was applied for approximately 3 seconds from a height of 10 cm.
OBJECTIVE: Despite recent attention to cognitive impairment in essential tremor, few studies examine rates of conversion to diagnoses of mild cognitive impairment and dementia. Development of dementia in essential tremor is associated with loss of functional ability and a doubling of mortality rate. This prospective, longitudinal study comprehensively reports the prevalence and incidence of, and the annual rates of conversion to, mild cognitive impairment and dementia in an essential tremor cohort.
METHODS: Patients underwent detailed cognitive assessments and were assigned diagnoses of normal cognition, mild cognitive impairment, or dementia. There were 222 patients at baseline (mean age = 79.3 ± 9.7 years), and 177 patients participated in follow-up evaluations at 18, 36, 54, and 72 months (mean years of observation = 5.1 ± 1.7). Data were compared to those of historical controls and Parkinson disease patients.
RESULTS: The cumulative prevalence of dementia and average annual conversion rate of mild cognitive impairment to dementia were 18.5% and 12.2%, nearly three times higher than rates in the general population, and approximately one half the magnitude of those reported for Parkinson disease patients. The cumulative prevalence of mild cognitive impairment (26.6%) was almost double that of the general population, but less than that in Parkinson disease populations.
INTERPRETATION: We present the most complete exposition of the longitudinal trajectory of cognitive impairment in an essential tremor cohort yet presented. The prevalence of and conversion rates to dementia in essential tremor fall between those associated with the natural course of aging and the more pronounced rates observed in Parkinson disease. ANN NEUROL 2024;95:1193-1204.
The twenty participants in the intervention arm will undergo a pre-assessment, post assessment, and a three month follow-up assessment. The pre and post assessments will ask participants to 1) fill out questionnaires to measure lifestyle, stress, meditations habits, and sleep impairment, 2) take a blood sample, 3) use a BodyMedia's Sensewear® armband for a week, and 4) provide salivary cortisol levels. The three month follow-up will repeat everything done if the first two assessments, excluding the blood sample. The intervention arm will also attend the weekly two and a half hour Mindfulness-Based Cancer Survivorship (MBSC) four-week program between the pre and post assessments.
A medication dispensing system includes an automated dispensing device that includes cells with electronically activated locks. The device is configured to detect when medication counts in the cells fall below predetermined thresholds. The system further includes a plurality of first electronic devices that are associated with some of the cells and that have imagers. In response to any of the medication counts in the cells being below the predetermined threshold, the automated dispensing device is configured to automatically send a replenishment needed notification to the first electronic device associated with the cell. That first electronic device is configured to transmit a picture of a medication to a second electronic device. In response to a positive verification by a user of the second electronic device that the medication in the picture is the correct medication, the second electronic device is configured to transmit an unlock signal to the automated dispensing device.
PURPOSE: A 2-sulfanyl-benzimidazole-4-carboximidazole derivative is provided to repair damaged DNA and suppress poly(ADP-ribose)polymerase-1(PARP-1) which is an enzyme causing cell damage and apoptosis. CONSTITUTION: A 2-sulfanyl-benzimidazole-4-carboximidazole derivative is denoted by chemical formula 1. A 2-sulfanyl-benzimidazole-4-carboximidazole derivative is prepared by performing alkylation of a compound of chemical formula 2 and a compound of chemical formula 3. A basic catalyst is used in the preparation. The basic catalyst is carbonate including sodium carbonate, potassium carbonate, or cesium carbonate; hydroxide including potassium hydroxide or sodium hydroxide; hydride including sodium hydride; alkoxide including sodium methoxide and sodium t-butoxide; triethylamine; or pyridine. A pharmaceutical composition for preventing or treating diseases caused by over-activation contains the 2-sulfanyl-benzimidazole-4-carboximidazole derivative or its pharmaceutically acceptable salt as an active ingredient.
Over 21 million Americans have limited English proficiency. About two-thirds of these individuals speak Spanish. Limited English proficiency has major adverse impacts on health and health care. Using trained medical interpreters may help overcome this language barrier. Compared to patients who need but don't get an interpreter, patients who use trained medical interpreters have better satisfaction, quality of care, and health outcomes. However, the outcomes of patients using interpreters is often poorer than that of English-speaking patients. This randomized controlled trial will test the utility of using interpreters as advocates for Spanish-speaking inner city patients with hypertension.
Protective sealing compositions in the form of molded rings or sheets for application around surgical fluid drainage openings, which compositions comprise a gelled mixture of a water-absorbing particulate hydrocolloid gum (e.g. Karayagum) and a non-toxic liquid polyhydroxy alcohol (e.g. glycerin or propylene glycol) are provided with increased resistance to the drained fluid (viz. urine or intestinal fluids) by incorporating a small amount of colloidal silica. Fumed silica is preferred. By limiting the amount of silica added appreciable reductions in the wet tack and/or dry tack of the composition can be avoided.
Cancer of the head and neck encompasses a wide range of cancers, including oral and oropharyngeal cancers. Oral cancer is often diagnosed at advanced stages and has a dismal prognosis. Piscidin-1, a marine antimicrobial peptide (AMP) containing approximately 22 amino acids, also exhibits significant anticancer properties. We investigated the possible anti-oral cancer effects of piscidin-1 and clarified the mechanisms underlying these effects. We treated the oral squamous cell carcinoma cell lines OC2 and SCC4 with piscidin-1. Cell viability and the expression of different hallmark apoptotic molecules, including reactive oxygen species (ROS), were tested using the appropriate MTT assay, flow cytometry and western blotting assays, and human umbilical vein endothelial cell (HUVEC) wound healing, migration, and tube formation (angiogenesis) assays. Piscidin-1 increases cleaved caspase 3 levels to induce apoptosis. Piscidin-1 also increases ROS levels and intensifies oxidative stress in the endoplasmic reticulum and mitochondria, causing mitochondrial dysfunction. Additionally, it decreases the oxygen consumption rates and activity of mitochondrial complexes I-V. As expected, the antioxidants MitoTEMPOL and N-acetylcysteine reduce piscidin-1-induced ROS generation and intracellular calcium accumulation. Piscidin-1 also inhibits matrix metalloproteinase (MMP)-2/-9 expression in HUVECs, affecting migration and tube formation angiogenesis. We demonstrated that piscidin-1 can promote apoptosis via both intrinsic and extrinsic apoptotic pathways and findings indicate that piscidin-1 has anti-proliferative and anti-angiogenic properties in oral cancer treatment. Our study on piscidin-1 thus provides a basis for future translational anti-oral cancer drug research and a new theoretical approach for anti-oral cancer clinical research.
Urine, or extracts therefrom, containing the follicle hormone is treated with reagents for ketonic compounds whereby precipitates of condensation products are obtained from which the follicle hormone may be split off, as by boiling with dilute acids or by double decomposition with aldehydes or ketones.  The reagents specified are hydroxylamine, hydrazines, semicarbazide, thiosemicarbazide, aminoguanidine and their substitution products.  According to examples: (1) a solution of semicarbazide in acetic acid is added to filtered urine, kieselguhr is added and the insoluble reaction product is filtered off, and boiled with alcoholic hydrochloric acid; the reaction mixture is extracted with ether, the ether evaporated and the residue purified by treatment with ethyl acetate and petrol ether and subsequent recrystallization from acetic acid or alcohol; (2) mares' urine is concentrated and steam distilled and the residue dissolved in alcohol and boiled with hydroxylamine acetate; the reaction mixture is concentrated, then diluted with water and decanted from the precipitate of oximes, which is then split up by heating with alcoholic hydrochloric acid.  Specifications 391,686 and 392,434 are referred to. The Specification as open to inspection under Sect. 91 refers also to the treatment of hormone-containing extracts from placenta or other organs or from vegetable matter. This subject-matter does not appear in the Specification as accepted.ALSO:Urine, or extracts therefrom, containing the follicle hormone is treated with reagents for ketonic compounds whereby precipitates of condensation products are obtained from which the follicle hormone may be split off, as by boiling with dilute acids or by double decomposition with aldehydes or ketones.  The reagents specified are hydroxylamine, hydrazines, semicarbazide, thiosemicarbazide, aminoguanidine and their substitution products. According to examples: (1) a solution of semicarbazide in acetic acid is added to filtered urine, kieselguhr is added and the insoluble reaction product is filtered off, and boiled with alcoholic hydrochloric acid; the reaction mixture is extracted with ether, the ether evaporated and the residue purified by treatment with ethyl acetate and petrol ether and subsequent recrystallization from acetic acid or alcohol; (2) mares' urine is concentrated and steam distilled and the residue dissolved in alcohol and boiled with hydroxylamine acetate; the reaction mixture is concentrated, then diluted with water and decanted from the precipitate of oximes, which is then split up by heating with alcoholic hydrochloric acid.  Specifications 391,686 and 392,434 are referred to.  The Specification as open to inspection under Sect. 91 refers also to the treatment of hormone-containing extracts from placenta or other organs of from vegetable matter.  This subject-matter does not appear in the Specification as accepted.